BLU-945 Plus Osimertinib Has Favorable Tolerability, Warrant

BLU-945 alone or in combination with osimertinib demonstrated early signals of clinical activity and was well tolerated in heavily pretreated patients with EGFR-mutant non–small cell lung cancer.

Related Keywords

Texas , United States , Yasiry Elamin , Bristol Myers Squibb Medarex , Spectrum Pharmaceuticals , University Of Texas Md Anderson Cancer , Division Of Cancer Medicine , Astrazeneca , Neck Medical Oncology , Cancer Medicine , Bayesian Optimal Interval , Turning Point , Blueprint Medicines , Elevation Oncology , Precision Therapeutics , Blu 945 Alone Or In Combination With Osimertinib , Heavily Pretreated Patients With Egfr Mutant Non Small Cell Lung Cancer , Symphony Trial , Nct04862780 , D , The University Of Texas Md Anderson Cancer ,